Abdoulaye Karaboué

Université Paris-Saclay — France

Medicine · Health Sciences

22h-index1.5kcitations74works16.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(33), Cancer Treatment and Pharmacology(21), Hepatocellular Carcinoma Treatment and Prognosis(19), Circadian rhythm and melatonin(17), Lung Cancer Treatments and Mutations(12)

Publications74 total

Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor Administration
JCO Oncology Practice·2025
Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: A bicentric bicontinental study.
Journal of Clinical Oncology·2025· 1 cited
Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study
EBioMedicine·2025· 25 citedOpen Access
Neo-wt- <i>RAS</i> in ctDNA: Is It Worth Using Anti-EGFR Therapies?
JCO Precision Oncology·2024
Role of the circadian timing system in the control of survival of patients receiving immunotherapy for cancer : Analysis of relevant mechanisms
theses.fr (ABES)·2024· 1 citedOpen Access
Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy?
British Journal of Cancer·2024· 52 citedOpen Access
Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis
ESMO Open·2024· 53 citedOpen Access
Overall Survival According to Time-of-Day of Treatment Administration in 713 Patients Receiving Immunochemotherapy as First Line Treatment Protocol for Advanced Non-Small Cell Lung Cancer: A Bicentric Bicontinental Study
SSRN Electronic Journal·2024Open Access
Rest–activity rhythm as a clinical biomarker in cancer
The Lancet Healthy Longevity·2023· 4 citedOpen Access
Improved survival on morning pembrolizumab with or without chemotherapy during initial treatment for stage IV non-small cell lung cancer.
Journal of Clinical Oncology·2023· 4 cited
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
Journal of Clinical Oncology·2023· 7 cited
Nivolumab timing as a major survival predictor in patients with stage IV non–small cell lung cancer.
Journal of Clinical Oncology·2022
The future of precise cancer chronotherapeutics
The Lancet Oncology·2022· 8 cited
Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer
Cancers·2022· 83 citedOpen Access
Circadian and chemotherapy-related changes in urinary modified nucleosides excretion in patients with metastatic colorectal cancer
Scientific Reports·2021· 5 citedOpen Access
Efficacy of an anti-EGFR after ctDNA conversion from mutated RAS status of metastatic colorectal cancer: Results of a pilot study.
Journal of Clinical Oncology·2021· 5 cited
Time-dependent efficacy of checkpoint inhibitor nivolumab in metastatic lung cancer patients.
Journal of Clinical Oncology·2021· 2 cited
Impact of assessment frequency of patient-reported outcomes: an observational study using an eHealth platform in cancer patients
Supportive Care in Cancer·2021· 17 cited
Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5‐fluorouracil and leucovorin combination as first‐ or second‐line treatment against metastatic colorectal cancer: Results from the International <scp>EORTC</scp> 05011 Trial
International Journal of Cancer·2020· 30 citedOpen Access
Undetectable<i>RAS</i>-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With<i>RAS</i>-Mutant Metastatic Colorectal Cancer
JCO Precision Oncology·2020· 27 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Françis Lévi(41), Pasquale F. Innominato(40), Mohamed Bouchahda(25), C. Focan(19), René Adam(17), Sylvie Giacchetti(11), Ayhan Ulusakarya(9), Carlos Carvalho(8), Salvatore Tumolo(8), Carlo Garufi(8), Rosine Guimbaud(7), Michel Ducreux(7), Mazen Haydar(7), Valérie Boige(6), Mohamed Hebbar(6), Denis Smith(6), Thierry Moreau(6), David Spiegel(6), T. Collon(6), Georg A. Bjarnason(6)